Celltrion

Activities: Manufacturing Pharmaceutical

Trending Articles

  1. Enhancing solubility with novel excipients With the growing prevalence of complex drug molecules, formulation is becoming ever more challenging. Novel excipients can unlock their potential, says Meera Raghuram, Director...
  2. SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
  3. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research...
  4. Buckland Group launches Quvara Medical after acquiring Becton Dickinson’s Swindon site to boost UK-EU medical manufacturing The acquisition establishes Quvara Medical as a new UK- and EU-based CMO offering GMP- and ISO-certified, high-volume manufacturing services to pharma and medtech clients
  5. SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Manufacturing

Wood to expand major biopharmaceutical manufacturing plant in South Korea

Wood will provide detailed engineering design for a new facility that will increase manufacturing capacity of biological medicines by eight million liquid vials per year
Regulatory

Bora and Celltrion team up on oral dosage form drugs

The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, one of the largest pharmaceutical production facilities in Taiwan
Manufacturing

South Korean Celltrion picks Lonza to diversify and expand manufacturing

Existing capacity sits at 190,000 L of drug substance each year
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Media

Asia and Latin America will drive biosimilars growth in next decade, says Visiongain

Established players will focus on monoclonal antibodies and licensing deals
Pharmaceutical

Hikma and CellTrion agree biosimilars distribution for MENA region

Total biologics market in MENA region expected to reach US$500m this year
Pharmaceutical

Hospira and Celltrion to develop and market biogenerics

<p>Hospira, a US supplier of generic injectable pharmaceuticals, has signed a distribution agreement with South Korea-based Celltrion and Celltrion Healthcare.</p>
Subscribe now